EC Agrees with Gilead to Supply 500,000 Courses of Anti COVID-19 Remdesivir

The European Commission (EC) has signed a contract with the American biopharmaceutical company Gilead Sciences for the supply of 500 thousand courses of Remdesivir drug to the European Union and partner countries for the treatment of the disease caused by the new coronavirus (COVID-19).

“The European Commission signed a contract with the pharmaceutical company Gilead for the supply of up to 500 thousand courses of treatment for Veklura, the brand name Remdesivir, as well as the opportunity to increase supplies beyond 500 thousand courses,” the EC said in a statement.

The document explains that 36 countries are involved in the procurement – all EU states, the European Economic Area, the United Kingdom, as well as six candidates and potential candidates for EU membership – Albania, the Republic of North Macedonia, Montenegro, Serbia, Kosovo and Bosnia and Herzegovina.


You might also like

Leave a Comment